Agenus (AGEN) Competitors $4.38 -0.17 (-3.74%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.38 0.00 (0.00%) As of 09/19/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. XOMA, EBS, LXRX, VNDA, CBIO, CDXS, IRWD, ACHV, SGMO, and FBIOShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include XOMA Royalty (XOMA), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Sangamo Therapeutics (SGMO), and Fortress Biotech (FBIO). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors XOMA Royalty Emergent Biosolutions Lexicon Pharmaceuticals Vanda Pharmaceuticals Crescent Biopharma Codexis Ironwood Pharmaceuticals Achieve Life Sciences Sangamo Therapeutics Fortress Biotech XOMA Royalty (NASDAQ:XOMA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Which has more risk & volatility, XOMA or AGEN? XOMA Royalty has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Do analysts rate XOMA or AGEN? XOMA Royalty currently has a consensus target price of $69.50, suggesting a potential upside of 89.37%. Agenus has a consensus target price of $14.50, suggesting a potential upside of 231.05%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than XOMA Royalty.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Agenus 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation and earnings, XOMA or AGEN? XOMA Royalty has higher earnings, but lower revenue than Agenus. XOMA Royalty is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA Royalty$28.49M15.57-$13.82M-$1.55-23.68Agenus$103.46M1.35-$227.21M-$7.15-0.61 Does the media favor XOMA or AGEN? In the previous week, XOMA Royalty had 5 more articles in the media than Agenus. MarketBeat recorded 5 mentions for XOMA Royalty and 0 mentions for Agenus. XOMA Royalty's average media sentiment score of 0.61 beat Agenus' score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media. Company Overall Sentiment XOMA Royalty Positive Agenus Neutral Is XOMA or AGEN more profitable? XOMA Royalty has a net margin of -27.57% compared to Agenus' net margin of -167.52%. XOMA Royalty's return on equity of 2.63% beat Agenus' return on equity.Company Net Margins Return on Equity Return on Assets XOMA Royalty-27.57% 2.63% 0.97% Agenus -167.52%N/A -81.04% Do institutionals & insiders hold more shares of XOMA or AGEN? 95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 7.2% of XOMA Royalty shares are held by company insiders. Comparatively, 5.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryXOMA Royalty beats Agenus on 12 of the 16 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.55M$3.15B$5.79B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-0.6121.0580.5726.86Price / Sales1.35445.77536.23125.79Price / CashN/A44.8326.0131.15Price / Book-0.349.6215.776.42Net Income-$227.21M-$53.02M$3.30B$271.73M7 Day Performance-1.57%1.43%3.93%2.82%1 Month Performance-3.10%3.42%5.32%6.60%1 Year Performance-25.00%11.20%80.88%28.60% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.6712 of 5 stars$4.38-3.7%$14.50+231.1%-25.0%$139.55M$103.46M-0.61440XOMAXOMA Royalty4.1548 of 5 stars$37.86+1.2%$69.50+83.6%+30.2%$457.73M$28.49M-24.4310EBSEmergent Biosolutions4.6832 of 5 stars$7.98-2.0%$13.50+69.2%+25.8%$425.74M$812.50M3.262,420LXRXLexicon Pharmaceuticals2.2988 of 5 stars$1.12-2.6%$3.23+187.9%-28.3%$407.01M$58.43M-3.39140VNDAVanda Pharmaceuticals4.1326 of 5 stars$4.38-2.9%$16.50+276.7%-2.6%$258.81M$203.47M-3.88290Positive NewsCBIOCrescent Biopharma4.0853 of 5 stars$12.22-2.2%$25.60+109.5%N/A$238.90M$10K-0.3550Gap UpCDXSCodexis2.848 of 5 stars$2.44+0.4%$11.00+350.8%-21.0%$220.26M$59.35M-2.94250Positive NewsIRWDIronwood Pharmaceuticals4.2956 of 5 stars$1.28-2.3%$4.94+285.9%-67.2%$207.91M$351.41M-25.59220Positive NewsACHVAchieve Life Sciences2.4793 of 5 stars$3.04-1.3%$14.67+382.5%-38.4%$155.34MN/A-2.0820Positive NewsShort Interest ↑SGMOSangamo Therapeutics2.909 of 5 stars$0.50-0.9%$4.50+799.5%-43.1%$150.95M$57.80M-1.73480Positive NewsFBIOFortress Biotech2.6718 of 5 stars$3.55-8.7%$16.50+364.8%+145.5%$105.63M$59.30M-3.38170Positive NewsAnalyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies XOMA Royalty Alternatives Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Crescent Biopharma Alternatives Codexis Alternatives Ironwood Pharmaceuticals Alternatives Achieve Life Sciences Alternatives Sangamo Therapeutics Alternatives Fortress Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGEN Stock Alerts